Breaking News
June 7, 2007
Amgen will acquire Alantos, a private company developing drugs for diabetes and inflammatory diseases, for $300 million in cash. Alantos' lead drug candidate, ALS 2-0426, is a DPP-IV inhibitor in Phase IIa development for the treatment of type II dia…
Read More »
June 7, 2007
Centocor, Inc. and Schering-Plough received approval from the European Commission for a new indication for Remicade for the treatment of severe, active Crohn's disease (CD) in pediatric patients, aged 6 to 17 years, who have not responded to conventi…
Read More »
June 7, 2007
Intertek Group has acquired Quantitative Technologies Inc. (QTI), a contract analytical research and development laboratory. QTI has served the North American market for more than 15 years, specializing in the pre-market launch stages of the drug and…
Read More »
June 6, 2007
Quintiles Transnational Corp. plans to build a new office near Edinburgh for its product development business in Scotland, including Quintiles Laboratories, and its NovaQuest group. The company will add 150 jobs in Scotland during the next four years…
Read More »
June 6, 2007
AstraZeneca's chief financial officer, Jon Symonds, is resigning from the company at the end of July. He will join investment bank Goldman Sachs as a managing director in mid-September, according to a company statement. The company has begun an exter…
Read More »
June 6, 2007
inVentiv Health, Inc.'s Clinical Solutions division has signed a new agreement with ClinPhone for a full suite of software and services to help accelerate clinical trials in the biopharmaceutical industry.
Under the terms of the agreement, inVen…
Read More »
June 5, 2007
Amgen has plans to acquire Ilypsa, a private biotechnology company developing non-absorbed drugs for renal disorders, for $420 million in cash. Ilypsa's lead drug candidate, ILY101, is a phosphate binder for the treatment of hyperphosphatemia in chro…
Read More »
June 5, 2007
Xceleron has signed a master services agreement with Sanofi-Aventis to assess the human metabolism of novel compounds in early clinical development. Prof. Colin Garner, Xceleron's chief executive officer, said, "Xceleron is delighted to be worki…
Read More »
June 5, 2007
Abbott has entered into a commercial license agreement with Dowpharma for its Pfenex Expression Technology, a Pseudomonas-based technology for biologic production. Abbott's product is a proprietary protein for which the company has already developed…
Read More »
June 5, 2007
Valeant Pharmaceuticals International has signed an agreement to sell its manufacturing facilities in Humacao, PR and Basel, Switzerland to Legacy Pharmaceuticals International. The sale includes the company's Reptilase product. Terms of the transact…
Read More »
June 4, 2007
AstraZeneca has acquired DSM Biologics' manufacturing facility in Montreal, Canada. The 66,000-sq.-ft. facility will be used to manufacture antibody drug candidates for AZ's clinical trials. The facility will be re-commissioned and AZ plans to begin…
Read More »
June 4, 2007
Parexel has extended its alliance with Phase Forward, allowing Parexel to continue to offer Phase Forward's InForm electronic data capture (EDC) product as part of its solution set. The two companies first partnered in 1999. Parexel also uses Phase F…
Read More »
June 4, 2007
Millennium Pharmaceuticals, Inc. has made two significant advancements in its Aurora A kinase program. The company achieved positive preliminary results from a Phase I study of MLN8054, a first-in-class small molecule to the Aurora A kinase. Also, th…
Read More »
June 1, 2007
Millennium Pharmaceuticals has appointed three members to its executive management team: chief scientific officer Joseph Bolen, Ph.D., chief medical officer Nancy Simonian, M.D., and senior vice president of non-clinical development sciences Peter Sm…
Read More »
June 1, 2007
Immunicon Corp. has entered into a research services agreement with Bristol-Myers Squibb (BMS) involving protein and molecular targets associated with circulating tumor cells (CTCs).
Leon Terstappen, M.D., Ph.D., chief scientific officer of Immu…
Read More »
